Help
RSS
API
Feed
Maltego
Contact
Domain > mike.steinbaugh.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2015-08-24
54.231.235.7
(
ClassC
)
2024-07-29
18.161.6.61
(
ClassC
)
2024-09-26
204.246.191.97
(
ClassC
)
2025-04-07
204.246.191.88
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: CloudFrontDate: Mon, 29 Jul 2024 04:10:35 GMTContent-Type: text/htmlContent-Length: 167Connection: keep-aliveLocation: https://mike.steinbaugh.com/X-Cache: Redire html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>CloudFront/center>/body>/html>
Port 443
HTTP/1.1 200 OKContent-Type: text/htmlContent-Length: 13163Connection: keep-aliveDate: Mon, 29 Jul 2024 04:10:36 GMTLast-Modified: Fri, 19 Jul 2024 10:41:36 GMTETag: 7b0f5dd92b3bb66b74158c79e4c2fb7aSe !DOCTYPE html>html langen idfront>head>title>Michael J. Steinbaugh, PhD/title>link relicon hrefhttps://steinbaugh.com/favicon.ico typeimage/x-icon />link relstylesheet typetext/css href/css/front.css />meta charsetUTF-8 />meta nameviewport contentwidthdevice-width />meta nametwitter:site content@mjsteinbaugh />/head>body>div idheadshot>img src/images/headshot.jpg alt />/div>p>strong>Michael J. Steinbaugh, PhD/strong>br />Director, Data, AI & Genome Sciences (DAGS), Omics Data Leadbr />Merck Research Laboratories (MRL)br />320 Bent Street, Cambridge, MA 02141br />a hrefmailto:mike@steinbaugh.com>mike@steinbaugh.com/a>/p>hr />p>Research scientist and team builder specializing in small molecule drugdiscovery, RNA biology, and genomics, with extensive experience in clinicaldevelopment from target identification through patient selection. Activeparticipant in open-source software development at a hrefhttps://acidgenomics.com/>Acid Genomics/a>./p>hr />h2 idexperience>Experience/h2>ul> li>strong>a hrefhttps://www.merck.com/>Merck/a>/strong>,Cambridge, MAbr />strong>Director, Data, AI & Genome Sciences (DAGS), Omics Data Lead/strong> — 2024-pres./li> li>strong>a hrefhttps://redonatx.com/>Redona Therapeutics/a>/strong>,Watertown, MAbr />Pre-clinical development of small molecules targeting RNA splicing andstability. ul> li>strong>Consultant/strong> — 2024-pres. ul> li>Contributed to clinical development efforts of lead CLK program./li> li>Engaged in business development efforts and asset out-licensingnegotiations./li> /ul> /li> li>strong>Director of Translational Science/strong> — 2021-24 ul> li>Lead bioinformatics and translational teams for CLK and TUT4/7 inhibitors./li> li>Engaged in licensing efforts related to lead CLK program./li> li>Contributed to Investigational New Drug (IND) application for CLKinhibitor./li> li>Deployed cloud-based genomics workflows on AWS and LatchBio platforms./li> /ul> /li
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]